Cargando…

Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug

Sinomenine (SIN) is a benzyltetrahydroisoquinoline-type alkaloid isolated from the dried plant root and stem of Sinomenium acutum (Thumb.) Rehd.et Wils, which shows potent anti-inflammatory and analgesic effects. As a transforming disease-modifying anti-rheumatic drug, SIN has been used to treat rhe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Lu, Chengcheng, Duan, Yanwen, Huang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781253/
https://www.ncbi.nlm.nih.gov/pubmed/36559313
http://dx.doi.org/10.3390/pharmaceutics14122820
_version_ 1784857028708007936
author Chen, Xin
Lu, Chengcheng
Duan, Yanwen
Huang, Yong
author_facet Chen, Xin
Lu, Chengcheng
Duan, Yanwen
Huang, Yong
author_sort Chen, Xin
collection PubMed
description Sinomenine (SIN) is a benzyltetrahydroisoquinoline-type alkaloid isolated from the dried plant root and stem of Sinomenium acutum (Thumb.) Rehd.et Wils, which shows potent anti-inflammatory and analgesic effects. As a transforming disease-modifying anti-rheumatic drug, SIN has been used to treat rheumatoid arthritis over twenty-five years in China. In recent years, SIN is also in development for use against other disorders, including colitis, pain, traumatic brain injury, and uveitis. However, its commercial hydrochloride (SIN-HCl) shows low oral bioavailability and certain allergic reactions in patients, due to the release of histamine. Therefore, a large number of pharmaceutical strategies have been explored to address these liabilities, such as prolonging release behaviors, enhancing skin permeation and adsorption for transdermal delivery, targeted SIN delivery using new material or conjugates, and co-amorphous technology. This review discusses these different delivery strategies and approaches employed to overcome the limitations of SIN for its efficient delivery, in order to achieve improved bioavailability and reduced side effects. The potential advantages and limitations of SIN delivery strategies are elaborated along with discussions of potential future SIN drug development strategies.
format Online
Article
Text
id pubmed-9781253
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97812532022-12-24 Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug Chen, Xin Lu, Chengcheng Duan, Yanwen Huang, Yong Pharmaceutics Review Sinomenine (SIN) is a benzyltetrahydroisoquinoline-type alkaloid isolated from the dried plant root and stem of Sinomenium acutum (Thumb.) Rehd.et Wils, which shows potent anti-inflammatory and analgesic effects. As a transforming disease-modifying anti-rheumatic drug, SIN has been used to treat rheumatoid arthritis over twenty-five years in China. In recent years, SIN is also in development for use against other disorders, including colitis, pain, traumatic brain injury, and uveitis. However, its commercial hydrochloride (SIN-HCl) shows low oral bioavailability and certain allergic reactions in patients, due to the release of histamine. Therefore, a large number of pharmaceutical strategies have been explored to address these liabilities, such as prolonging release behaviors, enhancing skin permeation and adsorption for transdermal delivery, targeted SIN delivery using new material or conjugates, and co-amorphous technology. This review discusses these different delivery strategies and approaches employed to overcome the limitations of SIN for its efficient delivery, in order to achieve improved bioavailability and reduced side effects. The potential advantages and limitations of SIN delivery strategies are elaborated along with discussions of potential future SIN drug development strategies. MDPI 2022-12-16 /pmc/articles/PMC9781253/ /pubmed/36559313 http://dx.doi.org/10.3390/pharmaceutics14122820 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chen, Xin
Lu, Chengcheng
Duan, Yanwen
Huang, Yong
Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug
title Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug
title_full Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug
title_fullStr Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug
title_full_unstemmed Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug
title_short Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug
title_sort recent advancements in drug delivery of sinomenine, a disease-modifying anti-rheumatic drug
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781253/
https://www.ncbi.nlm.nih.gov/pubmed/36559313
http://dx.doi.org/10.3390/pharmaceutics14122820
work_keys_str_mv AT chenxin recentadvancementsindrugdeliveryofsinomenineadiseasemodifyingantirheumaticdrug
AT luchengcheng recentadvancementsindrugdeliveryofsinomenineadiseasemodifyingantirheumaticdrug
AT duanyanwen recentadvancementsindrugdeliveryofsinomenineadiseasemodifyingantirheumaticdrug
AT huangyong recentadvancementsindrugdeliveryofsinomenineadiseasemodifyingantirheumaticdrug